Form 4: Relmada Therapeutics CFO Maged Shenouda Reports Stock Option Transactions

Maged Shenouda, CFO of Relmada Therapeutics, reports acquiring and forfeiting stock options related to the company's 2021 Equity Incentive Plan.

Summary

• On May 24, 2024, Relmada Therapeutics CFO Maged Shenouda reported transactions involving stock options.
• Shenouda became entitled to receive options for 54,624 additional shares under the company's 2021 Equity Incentive Plan due to expirations, cancellations, forfeitures, and terminations of other outstanding awards.
• Simultaneously, Shenouda voluntarily forfeited a portion of his existing option award, also equal to 54,624 shares, so that those shares can be allocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Shenouda directly owns 136,714 stock options with an exercise price of $2.48 and 82,090 stock options with an exercise price of $2.48.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option transactions. The forfeiture to benefit other employees is a slightly positive signal.

Positives

• The forfeiture of options by the CFO to benefit other employees could be seen as a positive gesture towards employee equity and morale.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their compensation packages for executives.

Stakeholder Impact

• The forfeiture of options by the CFO to benefit other employees could improve employee morale and align interests.

Key Dates

Keywords

stock options, Relmada Therapeutics, RLMD, Form 4, Maged Shenouda, CFO, Equity Incentive Plan, beneficial ownership